3'-hydroxybiphenyl-4-carboxylic acid amide | 779341-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3'-hydroxybiphenyl-4-carboxylic acid amide
• 英文别名: 3′-hydroxy-4-biphenylcarboxamide；4-(3-hydroxyphenyl)benzamide；3'-hydroxy-4-biphenylcarboxamide；3'-Hydroxy-[1,1'-biphenyl]-4-carboxamide
• CAS: 779341-13-8
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: SQTOIQOXWRXHJA-UHFFFAOYSA-N

物化性质

• 熔点：
  187-189 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• 沸点：
  457.4±38.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3'-hydroxybiphenyl-4-carboxylic acid amide 在 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 生成 3′-[(2-{[2-(2-thienyl)ethyl]amino}ethyl)oxy]-4-biphenylcarboxamide
  参考文献：
  名称：

  作为阿片样物质受体的拮抗剂或反向激动剂的 新型化合物

  摘要：

  本发明涉及作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物。本发明提供作为一种或多种阿片样物质受体上的拮抗剂或反向激动剂的新型化合物、含有该新化合物的药物组合物及它们的制备方法。

  公开号：

  CN102516115B
• 作为产物：
  描述：

  对溴苯甲胺 在 四(三苯基膦)钯 、 三溴化硼 、 sodium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 8.0h， 生成 3'-hydroxybiphenyl-4-carboxylic acid amide
  参考文献：
  名称：

  Cyclohexylcarbamic Acid 3‘- or 4‘-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors:  Synthesis, Quantitative Structure−Activity Relationships, and Molecular Modeling Studies

  摘要：

  Fatty acid amide hydrolase (FAAH) is a promising target for modulating endocannabinoid and fatty acid ethanolamide signaling, which may have important therapeutic potential. We recently described a new class of O-arylcarbamate inhibitors of FAAH, including the cyclohexylcarbamic acid biphenyl-3-yl ester URB524 (half-maximal inhibitory concentration, IC50 = 63 nM), which have significant anxiolytic-like properties in rats. In the present study, by introducing a selected group of substituents at the meta and para positions of the distal phenyl ring of URB524, we have characterized structure-activity profiles for this series of compounds and shown that introduction of small polar groups in the meta position greatly improves inhibitory potency. Most potent in the series was the m-carbamoyl derivative URB597 (4i, IC50 = 4.6 nM). Furthermore, quantitative structure-activity relationship (QSAR) analysis of an extended set of meta-substituted derivatives revealed a negative correlation between potency and lipophilicity and suggested that small-sized substituents may undertake polar interactions with the binding pocket of the enzyme. Docking studies and molecular dynamics simulations, using the crystal structure of FAAH, indicated that the O-biphenyl scaffold of the carbamate inhibitors can be accommodated within a lipophilic region of the substrate-binding site, where their folded shape mimics the initial 10-12 carbon atoms of the arachidonyl moiety of anandamide (a natural FAAH substrate) and methyl arachidonyl fluorophosphonate (a nonselective FAAH inhibitor). Moreover, substituents at the meta position of the distal. phenyl ring can form hydrogen bonds with atoms located on the polar section of a narrow channel pointing toward the membrane-associated side of the enzyme. The structure-activity characterization reported here should help optimize the pharmacodynamic and pharmacokinetic properties of this class of compounds.

  DOI：

  10.1021/jm031140x

文献信息

• METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：IGNAR DIANE MICHELE

  公开号：US20100113512A1

  公开（公告）日：2010-05-06

  A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

  使用含有新型阿片受体拮抗剂或反向激动剂的药物组合物治疗暴食症、厌食症、暴食症、过度药物或酒精使用或其他未明确指定的进食障碍的治疗方法。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：Cowan David John

  公开号：US20110124559A1

  公开（公告）日：2011-05-26

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物，它们是阿片受体的拮抗剂或逆向激动剂，含有它们的药物组合物，以及它们的制备方法。
• [EN] THROMBOXANE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DU THROMBOXANE
  申请人：UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN

  公开号：WO2016203314A1

  公开（公告）日：2016-12-22

  The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G2/PGH2, 20-hydroxyeicosatetraenoic acid (20-HETE) and the free -radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F2α)i play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.

  该发明涉及作为血栓素（TX）A2受体或T前列腺素受体（TP）拮抗剂的新型化学实体，以及它们在治疗人类疾病中的应用，其中包括血栓素（TX）A以及所有其他作为TP偶发配体的剂，包括内过氧化物前列腺素（PG）G2/PGH2、20-羟基二十碳四烯酸（20-HETE）和自由基衍生的异前列腺素（如8-异前列腺素（PG）F2α），这些化合物起作用。该发明的化合物最好包括苯磺酰脲，其中苯环被取代的双苯氧基基团（例如，在2位）和一个腈基团（例如，在5位）取代，这些化合物表现出有望成为TP-异构体选择性TP拮抗剂的良好结果。
• [EN] SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME<br/>[FR] LIGANDS SÉLECTIFS DU RÉCEPTEUR DOPAMINERGIQUE 3 (D3) ET PROCÉDÉS POUR LES UTILISER
  申请人：UNIV MICHIGAN

  公开号：WO2010025235A1

  公开（公告）日：2010-03-04

  Potent and selective ligands for the dopamine 3 (D3) receptor are disclosed. The D3 receptor ligands have a structural formula (I) wherein X is C=O or SO2, R1 is C1-6 alkyl, R2 is aryl, heteroaryl, aryl, -(CH2)1-3aryl, or -(CH2)1-3heteroaryl, and n is 0 or 1. Methods of using the D3 receptor ligands in the treatment of diseases and conditions wherein modulation of the D3 receptor provides a benefit also are disclosed.

  本发明揭示了多巴胺3（D3）受体的有效和选择性配体。D3受体配体具有结构式（I），其中X为C=O或SO2，R1为C1-6烷基，R2为芳基、杂环芳基、芳基、-(CH2)1-3芳基或-(CH2)1-3杂环芳基，n为0或1。本发明还揭示了在治疗疾病和情况中使用D3受体配体的方法，其中调节D3受体能够带来益处。
• Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
  申请人：GlaxoSmithKline LLC

  公开号：US20140323487A1

  公开（公告）日：2014-10-30

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物是阿片受体拮抗剂或反向激动剂，药物组合物包含它们，以及它们的制备方法。